Sublingual Buprenorphine Is Associated with Increased Caries Experience and Altered Oral Microbial and Salivary Risk Factors
In the authors' words
Background: Sublingual buprenorphine (SLB) is commonly prescribed to treat opioid use disorder. Pharmacoepidemiologic studies suggest an association between SLB and severe dental caries, yet clinical investigations are lacking. Objective: To assess caries experience and caries-related risk factors among patients taking SLB. Methods: This pilot cross-sectional study enrolled 11 subjects taking SLB films, 10 taking SLB tablets, and 10 age- and sex-matched controls. Demographic, medical, dental, and behavioral data were collected. Caries examinations were performed. Salivary pH, buffering capacity, and flow rate were measured. Saliva and plaque levels of Mutans streptococci and Candida spp. were determined. Oral pH dynamics and salivary concentrations of buprenorphine, its metabolites, and naloxone were monitored. Results: Caries experience was greater in SLB subjects than controls and higher among tablet versus film subjects (p<0.05). SLB subjects exhibited lower salivary pH and buffering capacity (p<0.05), and elevated salivary levels of Mutans streptococci (p<0.05) and Candida spp. (p<0.001). SLB administration was associated with rapid oral acidification and prolonged recovery. Salivary buprenorphine exposure was elevated and correlated with baseline pH (p<0.01), suggesting ion trapping contributes to oral retention. Conclusion: Patients receiving SLB exhibit increased caries experience likely resulting from localized acidification favoring caries-associated microorganisms and prolonged oral exposure to buprenorphine.
Appeared: Tuesday, November 17. medRxiv. Preprint, not yet peer-reviewed.